Exencial Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Exencial Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,021	Closed	-$238K	–	566
2025 Q4	$238K	Buy	11,021 +11	+0.1%	+$214	0.01%	511
2025 Q3	$168K	Buy	11,010 +525	+5%	+$6.83K	0.01%	514
2025 Q2	$92.8K	Buy	10,485 +26	+0.2%	+$228	﹤0.01%	485
2025 Q1	$81.9K	Buy	+10,459	New	+$87.6K	﹤0.01%	491
2024 Q4	–	Sell	-25,000	Closed	-$328K	–	502
2024 Q3	$328K	Buy	25,000 +2,000	+9%	+$30.5K	0.01%	422
2024 Q2	$323K	Buy	23,000 +7,700	+50%	+$126K	0.01%	423
2024 Q1	$258K	Buy	15,300 +3,300	+28%	+$49.1K	0.01%	457
2023 Q4	$169K	Hold	12,000	–	–	0.01%	472
2023 Q3	$124K	Buy	+12,000	New	+$161K	0.01%	419

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Exencial Wealth Advisors's AVDL Position: Q1 2026 in Review

Exencial Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 11,021 shares — an estimated $238K sold.

Exencial Wealth Advisors first reported a position in AVDL in Q3 2023 and held it in 9 quarters. The position peaked at $328K in Q3 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Exencial Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Exencial Wealth Advisors sold 11,021 Avadel Pharmaceuticals shares in Q1 2026, an estimated $238K.
Exencial Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Exencial Wealth Advisors's Avadel Pharmaceuticals position peaked at $328K in Q3 2024.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Exencial Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.